Đề xuất các mạng lưới đồng biểu hiện và tương tác vật lý tối thiểu cần thiết liên quan đến sự phát triển cạn kiệt nhận thức ở người ở tuổi trung niên và tuổi già

Van Dyken P, Lacoste B (2018) Impact of metabolic syndrome on neuroinflammation and the blood–brain barrier. Front Neurosci 12:930 de Mello NP, Orellana AM, Mazucanti CH, de Morais LG, Scavone C, Kawamoto EM (2019) Insulin and autophagy in neurodegeneration. Front Neurosci 13:491. https://doi.org/10.3389/fnins.2019.00491 Karvani M, Simos P, Stavrakaki S, Kapoukranidou D (2019) Neurocognitive impairment in type 2 diabetes mellitus. Hormones:1–12 Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA (2018) Author correction: multiple sclerosis. Nat Rev Dis Primers 4(1):49. https://doi.org/10.1038/s41572-018-0050-3 Branco M, Ruano L, Portaccio E, Goretti B, Niccolai C, Patti F, Chisari C, Gallo P, Grossi P, Ghezzi A (2019) Aging with multiple sclerosis: prevalence and profile of cognitive impairment. Neurol Sci 40(8):1651–1657 Amato MP, Goretti B, Brescia Morra V, Gallo P, Zaffaroni M, Onofrj M, Cocco E, Borriello G, Zipoli V, Trojano M.Neurol Sci. 2020 May 1. https://doi.org/10.1007/s10072-020-04320-w Hou W-H, Li C-Y, Chang H-H, Sun Y, Tsai C-C (2017) A population-based cohort study suggests an increased risk of multiple sclerosis incidence in patients with type 2 diabetes mellitus. J Epidemiol 27(5):235–241 Hussein WI, Reddy SS (2006) Prevalence of diabetes in patients with multiple sclerosis. Diabetes Care 29(8):1984–1985 Marrie RA (2017) Comorbidity in multiple sclerosis: implications for patient care. Nat Rev Neurol 13(6):375–382 negrotto L, Farez MF, Correale J (2016) Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis. JAMA Neurol 73(5):520–528 Mallorquí-Bagué N, Lozano-Madrid M, Toledo E, Corella D, Salas-Salvadó J, Cuenca-Royo A, Vioque J, Romaguera D, Martínez JA, Wärnberg J (2018) Type 2 diabetes and cognitive impairment in an older population with overweight or obesity and metabolic syndrome: baseline cross-sectional analysis of the PREDIMED-plus study. Sci Rep 8(1):1–9 Li W, Lin S, Li G, Xiao S (2019) Prevalence, influence factors and cognitive characteristics of mild cognitive impairment in type 2 diabetes mellitus. Front Aging Neurosci 11:180 Albai O, Frandes M, Timar R, Roman D, Timar B (2019) Risk factors for developing dementia in type 2 diabetes mellitus patients with mild cognitive impairment. Neuropsychiatr Dis Treat 15:167–175 Arvanitakis Z, Shah RC, Bennett DA (2019) Diagnosis and management of dementia. Jama 322(16):1589–1599 Karantzoulis S, Galvin JE, Braak S, Mckhann MK, Jack S, Hodges B (2011) Distinguishing Alzheimer’s disease from other major forms of dementia. Expert Rev Neurother 11(11):1579–1591 Cunningham EL, McGuinness B, Herron B, Passmore AP (2015) Dementia. Ulster Med J 84(2):79–87 Lin Y-F, Smith AV, Aspelund T, Betensky RA, Smoller JW, Gudnason V, Launer LJ, Blacker D (2019) Genetic overlap between vascular pathologies and Alzheimer’s dementia and potential causal mechanisms. Alzheimers Dement 15(1):65–75. https://doi.org/10.1016/j.jalz.2018.08.002 Rotermund C, Machetanz G, Fitzgerald JC (2018) The therapeutic potential of metformin in neurodegenerative diseases. Front Endocrinol 9:400 Shi Q, Liu S, Fonseca VA, Thethi TK, Shi L (2019) Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. BMJ Open 9(7):e024954 Campbell JM, Stephenson MD, De Courten B, Chapman I, Bellman SM, Aromataris E (2018) Metformin use associated with reduced risk of dementia in patients with diabetes: a systematic review and meta-analysis. J Alzheimers Dis 65(4):1225–1236 Caberlotto L, Nguyen T-P, Lauria M, Priami C, Rimondini R, Maioli S, Cedazo-Minguez A, Sita G, Morroni F, Corsi M (2019) Cross-disease analysis of Alzheimer’s disease and type-2 diabetes highlights the role of autophagy in the pathophysiology of two highly comorbid diseases. Sci Rep 9(1):1–13 Lassmann H, van Horssen J (2011) The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett 585(23):3715–3723 McKusick VA (2007) Mendelian Inheritance in Man and its online version, OMIM. Am J Hum Genet 80(4):588–604 Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork PJN (2018) STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 47(D1):D607–D613 Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CTJN (2010) The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 38(suppl_2):W214–W220 Alanis-Lobato G, Andrade-Navarro MA, Schaefer MH (2016) HIPPIE v2. 0: enhancing meaningfulness and reliability of protein–protein interaction networks. Nucleic Acids Res gkw985 Doncheva NT, Morris JH, Gorodkin J, Jensen LJ (2018) Cytoscape StringApp: network analysis and visualization of proteomics data. J Proteome Res 18(2):623–632 Ikonomovic MD, Mi Z, Abrahamson EEJ (2017) Disordered APP metabolism and neurovasculature in trauma and aging: combined risks for chronic neurodegenerative disorders. Ageing Res Rev 34:51–63 Pietroboni AM, Scarioni M, Carandini T, Basilico P, Cadioli M, Giulietti G, Arighi A, Caprioli M, Serra L, Sina C (2018) CSF β-amyloid and white matter damage: a new perspective on Alzheimer’s disease. J Neurol Neurosurg Psychiatry 89(4):352–357 Gehrmann J, Banati RB, Cuzner ML, Kreutzberg GW, Newcombe J (1995) Amyloid precursor protein (APP) expression in multiple sclerosis lesions. Glia 15(2):141–151 An YA, Crewe C, Asterholm IW, Sun K, Chen S, Zhang F, Shao M, Funcke J-B, Zhang Z, Straub L (2019) Dysregulation of amyloid precursor protein impairs adipose tissue mitochondrial function and promotes obesity. Nat Metab 1(12):1243–1257 Hancock ML, Meyer RC, Mistry M, Khetani RS, Wagschal A, Shin T, Sui SJH, Näär AM, Flanagan JG (2019) Insulin receptor associates with promoters genome-wide and regulates gene expression. Cell 177(3):722–736.e722 Galle SA, Van Der Spek A, Drent ML, Brugts MP, Scherder EJ, Janssen JA, Ikram MA, Van Duijn CM (2019) Revisiting the role of insulin-like growth factor-I receptor stimulating activity and the apolipoprotein E in Alzheimer’s disease. Front Aging Neurosci 11:20 Soto M, Cai W, Konishi M, Kahn CR (2019) Insulin signaling in the hippocampus and amygdala regulates metabolism and neurobehavior. Proc Natl Acad Sci 116(13):6379–6384 Lainampetch J, Panprathip P, Phosat C, Chumpathat N, Prangthip P, Soonthornworasiri N, Puduang S, Wechjakwen N, Kwanbunjan K (2019) Association of tumor necrosis factor alpha, interleukin 6, and C-reactive protein with the risk of developing type 2 diabetes: a retrospective cohort study of rural Thais. J Diabetes Res 2019:1–9 Subedi L, Lee SE, Madiha S, Gaire BP, Jin M, Yumnam S, Kim SY (2020) Phytochemicals against TNFα-mediated neuroinflammatory diseases. Int J Mol Sci 21(3):764 Hu WT, Howell JC, Ozturk T, Gangishetti U, Kollhoff AL, Hatcher-Martin JM, Anderson AM, Tyor WR (2019) CSF cytokines in aging, multiple sclerosis, and dementia. Front Immunol 10 Griñán-Ferré C, Marsal-García L, Bellver-Sanchis A, Kondengaden SM, Turga RC, Vázquez S, Pallàs M (2019) Pharmacological inhibition of G9a/GLP restores cognition and reduces oxidative stress, neuroinflammation and β-amyloid plaques in an early-onset Alzheimer’s disease mouse model. Aging (Albany NY) 11(23):11591–11608 Zuliani G, Ranzini M, Guerra G, Rossi L, Munari M, Zurlo A, Volpato S, Atti A, Ble A, Fellin R (2007) Plasma cytokines profile in older subjects with late onset Alzheimer’s disease or vascular dementia. J Psychiatr Res 41(8):686–693 King E, Thomas A (2017) Systemic inflammation in Lewy body diseases. Alzheimer Dis Assoc Disord 31(4):346–356 Belarbi K, Jopson T, Tweedie D, Arellano C, Luo W, Greig NH, Rosi S (2012) TNF-α protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. J Neuroinflammation 9(1):23 Moore AM, Mahoney E, Dumitrescu L, De Jager PL, Koran MEI, Petyuk VA, Robinson RA, Ruderfer DM, Cox NJ, Schneider JA (2020) APOE ε4-specific associations of VEGF gene family expression with cognitive aging and Alzheimer’s disease. Neurobiol Aging 87:18–25 Zafar MI, Mills K, Ye X, Blakely B, Min J, Kong W, Zhang N, Gou L, Regmi A, Hu SQ (2018) Association between the expression of vascular endothelial growth factors and metabolic syndrome or its components: a systematic review and meta-analysis. Diabetol Metab Syndr 10(1):62 Staels W, Heremans Y, Heimberg H, De Leu N (2019) VEGF-A and blood vessels: a beta cell perspective. Diabetologia:1–8 Azimi G, Ranjbaran F, Arsang-Jang S, Ghafouri-Fard S, Mazdeh M, Sayad A, Taheri M (2020) Upregulation of VEGF-A and correlation between VEGF-A and FLT-1 expressions in Iranian multiple sclerosis patients. Neurol Sci:1–7 El Kadmiri N, Slassi I, El Moutawakil B, Nadifi S, Tadevosyan A, Hachem A, Soukri A (2014) Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer’s disease. Pathol Biol 62(6):333–336 Feng S, Shi T, Qiu J, Yang H, Wu Y, Zhou W, Wang W, Wu H (2017) Notch1 deficiency in postnatal neural progenitor cells in the dentate gyrus leads to emotional and cognitive impairment. FASEB J 31(10):4347–4358 Cho S-J, Yun S-M, Jo C, Jeong J, Park MH, Han C, Koh YH (2019) Altered expression of Notch1 in Alzheimer’s disease. PLoS One 14(11):e0224941 Caputo V, Termine A, Strafella C, Giardina E, Cascella R (2020) Shared (epi) genomic background connecting neurodegenerative diseases and type 2 diabetes. World J Diabetes 11(5):155–164 Hu S, Cho E-H, Lee J-Y (2020) Histone deacetylase 9: its role in the pathogenesis of diabetes and other chronic diseases. Diabetes Metab J 44(2):234–244